Bio Waivers High Impact Factor Journals:
Bio waivers conceded dependent on inaccessibility/detachment of comparator/trailblazer item. There have been issues on the inaccessibility/unavailability of comparator/pioneer items for certain dynamic fixings since the execution of the BE prerequisite whereby the comparator/trailblazer item is not, at this point accessible in Malaysia. In any case, the comparator/trend-setter item might be as yet accessible around the world. The Drug Control Authority (DCA) at its 171stmeeting (30thJune 2005) endorsed the proposition by the National Working Committee for BE Studies to give exclusion from submitting BE contemplates (bio waiver) because of inaccessibility of the comparator item for a couple of medication substances/dynamic pharmaceutical fixings. Issues on the inaccessibility/unavailability of comparators have been managed as a case to case premise by the National Working Committee for BE Studies. The National Working Committee for BE Studies is commanded to not just help and encourage the lead of BE Studies in Malaysia yet additionally to talk about BE connected issues and to figure suggestion and answers for these issues. BE contemplates that are directed utilizing comparator/pioneer items that are not, at this point accessible in Malaysia will nullify the point/extreme target in exhibiting compatibility between conventional items and comparator/trend-setter items that are accessible in Malaysia. The Drug Control Authority (DCA) at its 271st gathering (sixteenth December 2013) affirmed the suggestion that nonexclusive items may/will be allowed bio waiver in the event that it satisfies ALL of the accompanying models: The comparator/pioneer item has been enlisted with DCA before the execution of the prerequisite for bioequivalence contemplates that is before 1999 and the enrolment status of the said comparator/trailblazer item is either drop, pulled back, ended or terminated
High Impact List of Articles
-
The therapeutic effect of combined therapy of hemopoietin and methylprednisolone in treatment of spinal cord ischemia-reperfusion injury of patient with cervical spondylotic myelopathy and its influence to the level of serum IL-1β, IL-1Ra and IL- 8
Qin Hao, Juan Shen & Lin Zhao
Research Article: Pharmaceutical Bioprocessing
-
The therapeutic effect of combined therapy of hemopoietin and methylprednisolone in treatment of spinal cord ischemia-reperfusion injury of patient with cervical spondylotic myelopathy and its influence to the level of serum IL-1β, IL-1Ra and IL- 8
Qin Hao, Juan Shen & Lin Zhao
Research Article: Pharmaceutical Bioprocessing
-
Synthesis and x-ray crystallographic studies of azatricyclo-sulfonamide derivatives
Lakshminarayanan Karthik, Jagadeesan Ganapathy, Pennathur Gautam & Gunasekaran Krishnasamy*
Research Article: Pharmaceutical Bioprocessing
-
Synthesis and x-ray crystallographic studies of azatricyclo-sulfonamide derivatives
Lakshminarayanan Karthik, Jagadeesan Ganapathy, Pennathur Gautam & Gunasekaran Krishnasamy*
Research Article: Pharmaceutical Bioprocessing
-
Industrial application of impurity flocculation to streamline antibody purification processes
Michael Felo, Yun Kenneth Kang*, James Hamzik, Paul Balderes and Dale L Ludwig
Review Article: Pharmaceutical Bioprocessing
-
Industrial application of impurity flocculation to streamline antibody purification processes
Michael Felo, Yun Kenneth Kang*, James Hamzik, Paul Balderes and Dale L Ludwig
Review Article: Pharmaceutical Bioprocessing
-
Harnessing Chinese hamster ovary cell proteomics for biopharmaceutical processing
Amit Kumar, Kelley M Heffner, Joseph Shiloach, Michael J Betenbaugh and Deniz Baycin-Hizal*
Review Article: Pharmaceutical Bioprocessing
-
Harnessing Chinese hamster ovary cell proteomics for biopharmaceutical processing
Amit Kumar, Kelley M Heffner, Joseph Shiloach, Michael J Betenbaugh and Deniz Baycin-Hizal*
Review Article: Pharmaceutical Bioprocessing
-
Considerations in upstream bioprocess
monitoring and statistical data analysis
in the
context of process analytical technology and
quality by design
Gerald Striedner & Karl Bayer
Review Article: Pharmaceutical Bioprocessing
-
Considerations in upstream bioprocess
monitoring and statistical data analysis
in the
context of process analytical technology and
quality by design
Gerald Striedner & Karl Bayer
Review Article: Pharmaceutical Bioprocessing
Relevant Topics in Clinical